GlaxoSmithKline Inc. is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Based in Mississauga, Ontario, the company employs more than 2,800 people across Canada. Employees in Canada work to discover, develop, manufacture and market new medicines for the treatment of migraine, asthma, HIV/AIDS and other infectious diseases, cancer, diabetes, depression and gastrointestinal and cardiovascular disorders. The company is part of U.K.-based GlaxoSmithKline plc. In 1997 GlaxoSmithKline employees voted to make a substantial, long-term commitment to the cause of hospice palliative care as a way to make a difference and have a greater impact on the quality of people’s lives.

The GlaxoSmithKline Foundation was established in Canada by GlaxoSmithKline Inc. to help enhance the quality of life for Canadians. The Foundation expresses its strong commitment to quality of life by focusing on health promotion, science education, local community projects, and its employee cause of choice, hospice palliative care. By supporting and working with many dedicated organizations, The GlaxoSmithKline Foundation has become a creative force for community wellness.